Hypothesis

Transiently senescent fibroblasts that appear during acute tissue injury secrete a specialized SASP enriched in latent TGF‑β1, MMP‑9, and ADAMTS‑5, which together generate a reversible, proteolytic‑rich provisional extracellular matrix (ECM). This matrix scaffolds myofibroblast alignment, facilitates controlled collagen fibrillogenesis, and later is cleared as the senescence program wanes. Premature removal of these cells with senolytics aborts matrix remodeling, leading to excess, disorganized collagen deposition and impaired functional recovery.

Mechanistic Rationale

1. SASP isoform switch – Transient senescence is characterized by an early SASP dominated by growth‑factor‑binding proteins (e.g., IGFBP‑5, fibrillin‑1) and matrix metalloproteinases, whereas chronic senescence shifts toward IL‑1α/IL‑8‑driven inflammation [4]. We propose that the early SASP includes latent TGF‑β1 complexed with LTBP‑1 and MMP‑9, enabling spatially restricted activation of TGF‑β only after MMP‑mediated cleavage.

2. Matrix‑bound growth factor reservoir – By depositing latent TGF‑β within a MMP‑9‑rich meshwork, senescent cells create a sink that prevents premature TGF‑β signaling, which would otherwise drive fibroblast‑to‑myofibroblast transition and fibrosis. The reservoir is gradually released as MMP‑9 activity declines, allowing timed myofibroblast maturation.

3. Feedback to immune clearance – The proteolytic SASP also releases chemotactic fragments (e.g., elastin peptides) that attract macrophages tasked with senocyte removal, linking matrix remodeling to im

Aging of the enteric nervous system (ENS) specifically reduces cholinergic neurotransmission, weakening the vagal anti‑inflammatory reflex that normally keeps mucosal immune activation in check. This loss permits microbiota‑derived LPS and secondary bile acids to chronically stimulate TLR4 and FXR pathways in colonic epithelium, elevating NF‑κB signaling and ROS production. Persistent oxidative stress accelerates DNA methylation drift in Lgr5+ stem cells, creating the patchwork epigenetic fields observed in nearly all colorectal cancers. Simultaneously, inflammation‑induced nitric oxide suppresses the expression of MLH1 and MSH2, directly impairing mismatch repair (MMR) activity. Thus, ENS cholinergic decline provides a mechanistic hub linking microbiome aging, epithelial epigenetic instability, and MMR deficiency—three processes that independently increase cancer risk but converge when neural regulation fails.

Testable predictions:

1. In aged mice, conditional ablation of ChAT+ enteric neurons will cause a measurable drop in colonic acetylcholine (measured by HPLC) coinciding with increased mucosal IL‑6, TNF‑α, and 8‑oxo‑dG levels.
2. These mice will show earlier onset of methylation‑age acceleration in isolated crypt stem cells (using the Horvath clock) and a higher frequency of MLH1/MSH2 loss‑of‑function patches compared with age‑matched controls.
3. Restoring cholinergic tone via systemic administration of a selective α7‑nAChR agonist (e.g., PNU‑282987) or via probiotic supplementation with acetylcholine‑producing Lactobacillus strains will normalize mucosal cytoki

Hypothesis: Oral urolithin A (UA) or its ellagitannin precursors act as a gut‑derived mitophagy signal that sets the brain’s mitochondrial homeostasis baseline, thereby driving longevity benefits independent of central nervous system‑directed interventions.

Mechanistic rationale

• UA is produced by specific gut bacteria from dietary polyphenols (e.g., punicalagins) and reaches systemic circulation via the portal vein.
• Recent work shows UA induces mitophagy in muscle and macrophages through the SIRT1‑PINK1‑Parkin axis, but its transport across the blood‑brain barrier (BBB) and direct neuronal effects remain untested.
• We propose that UA crosses the BBB via monocarboxylate transporters (MCT1) expressed on brain endothelial cells, where it activates SIRT1 in pericytes and astrocytes, leading to up‑regulation of PINK1‑mediated mitophagy in microglia and neurons.
• Enhanced mitophagy reduces mitochondrial ROS, lowers endothelial senescence, and tightens BBB integrity by increasing claudin‑5 and occludin expression (see [1] for SCFA‑BBB parallels).
• A secondary gut‑mediated effect occurs when UA‑producing taxa (e.g., Gordonibacter) shift the metabolite profile: they decrease phenylalanine‑catabolizing bacteria, lowering circulating phenylacetic acid (PAA) that drives endothelial senescence ([2]).
• The combined increase in neuronal mitophagy and decrease in circulating PAA restores neurovascular unit function, which in turn normalizes vagal afferent firing to the nucleus tractus solitarius, resetting autonomic tone toward parasympathetic dominance.
• This vagal feedbac

Hypothesis

Chronic activation of IKKβ/NF‑κB in gonadotropin‑releasing hormone (GnRH) neurons directly suppresses GnRH gene transcription through induction of Notch1‑ICD/Hes1 repressor complexes, a process initiated by microglial‑derived CXCL10 binding to CXCR3 on GnRH neurons.

Mechanistic Rationale

Aging hypothalamus exhibits IKKβ/NF‑κB activation in neural stem cells and glia, yet cell‑autonomous effects on GnRH neurons remain untested [1][2]. Microglia in the aged hypothalamus become PD‑1^hi and secrete CXCL10, which engages CXCR3 receptors on neurons to trigger NF‑κB signaling [3][4]. CXCR3 couples to Gαi proteins and can activate IKKβ via β‑arrestin–mediated scaffolding, a pathway documented in peripheral immune cells but unexplored in GnRH neurons. Once IKKβ is active, NF‑κB p65 translocates to the GnRH promoter and recruits co‑repressors that facilitate Notch1 intracellular domain (Notch1‑ICD) nuclear accumulation. Notch1‑ICD then complexes with Hes1 to bind E‑box motifs near the GnRH transcription start site, blocking RNA polymerase II recruitment and promoting histone deacetylation via HDAC1/2 recruitment. This dual repression—direct NF‑κB interference and Notch/Hes1‑mediated silencing—explains the observed decline in GnRH peptide output despite intact upstream kisspeptin signaling.

Testable Predictions

1. GnRH neuron‑specific IKKβ deletion (GnRH‑Cre;IKKβ^fl/fl) will prevent age‑dependent reduction in GnRH mRNA and peptide levels, even when systemic inflammation persists.
2. CXCR3 antagonism in aged mice will diminish IKKβ phosphorylation and p65 nucle

Hypothesis

Senescent enteroendocrine L-cells are not inert debris; they actively secrete a senescence‑associated secretory phenotype (SASP) packaged into exosomes that suppress proliferation of neighboring L‑cell progenitors and fine‑tune GLP‑1 release in the duodenal mucosa. Consequently, removing these cells with senolytics will lift the proliferative brake, expand the L‑cell pool, but disrupt the paracrine GLP‑1 signaling network, leading to altered glucose homeostasis.

Mechanistic rationale

1. SASP composition in enteroendocrine L‑cells – Drawing from pancreatic β‑cell data, senescent endocrine cells enrich SASP proteins involved in inflammation, stress response, and extracellular vesicle pathways (1). We predict that senescent L‑cells similarly load exosomes with TGF‑β, IL‑6, and specific microRNAs (e.g., miR‑29 family) that inhibit Wnt/β‑catenin signaling in stem/progenitor cells.
2. Paracrine GLP‑1 dominance – Only ~15 % of secreted GLP‑1 reaches the circulation; the majority acts locally (4). Thus, any alteration in the mucosal microenvironment will have outsized effects on nutrient‑induced GLP‑1 pulses.
3. Adaptive coordinator role – SASP can enforce senescence in adjacent cells while also recruiting immune modulators that preserve tissue integrity ([2](https://www.aging-us.com/news-room/The-Senescence-Associated-Secretory-Phenotype-Induces-Neuro

Hypothesis

Rapamycin improves endothelial function by inducing mitophagy that selectively removes damaged mitochondria, thereby reducing ROS and restoring eNOS coupling, while leaving senescent cell markers largely unchanged.

Mechanistic Rationale

• Rapamycin inhibits mTORC1, which activates ULK1‑dependent autophagy and, under stress, promotes PINK1/Parkin‑mediated mitophagy (1).
• Senescent endothelial cells exhibit persistent mTORC1 signaling due to defective nutrient sensing, yet their mitochondria are often depolarized and ROS‑producing (2).
• By enhancing mitophagy, rapamycin would lower mitochondrial ROS, decreasing superoxide that scavenges NO and drives eNOS uncoupling (3; 4).
• Reduced ROS would increase NO bioavailability and diminish NF‑κB activation, lowering ICAM‑1 expression without affecting the core senescent program (p16^Ink4a^, SASP) (5).
• This creates a “pseudo‑quiescent” endothelial state: improved vasodilatory capacity and lower inflammation, but the cells remain senescent and resistant to clearance (6).

Testable Predictions

1. In vivo: Aged mice treated with rapamycin for 8 weeks will show:
   • ↑ mitochondrial citrate synthase activity and ↓ MitoSOX fluorescence in isolated aortic endothelium.
   • ↑

Hypothesis

Age‑accumulated mitochondrial DNA (mtDNA) mutations reduce the expression or activity of the mitochondrially‑encoded SIRT3 deacetylase, leading to hyperacetylation of metabolic enzymes and DNA‑repair factors in germinal center B cells. This metabolic‑epigenetic block forces B cells to rely on glycolysis, stalls the oxidative‑phosphorylation (OxPhos) transition required for affinity maturation, and diminishes the efficiency of activation‑induced cytidine deaminase (AID)‑mediated somatic hypermutation (SHM). Consequently, the antibody repertoire contracts and affinity maturation fails, reproducing the aged humoral phenotype.

Mechanistic Rationale

1. mtDNA‑SIRT3 link – The SIRT3 gene is nuclear‑encoded but its activity depends on NAD+ generated by OxPhos; mtDNA damage lowers NAD+ levels, decreasing SIRT3 deacetylase activity {1}.
2. Acetyl‑mediated metabolic shift – Hypoactive SIRT3 hyperacetylates pyruvate dehydrogenase complex and succinate dehydrogenase, suppressing TCA flux and forcing a glycolytic phenotype, which is incompatible with the quiescent OxPhos state of mature germinal centers {2}.
3. DNA‑repair consequence – SIRT3 also deacetylates Ku70 and RAD51; loss of SIRT3 activity impairs non‑homologous end joining and homologous recombination, increasing the mutagenic load of AID‑induced DNA lesions and reducing successful SHM {3}.
4. **Clonal ou

Hypothesis

Telomere shortening in enterochromaffin (EC) cells directly reduces serotonin synthesis by altering chromatin state at the TPH1 locus, a process modulated by SIRT1 activity and gut‑derived short‑chain fatty acids (SCFAs).

Mechanistic Model

1. Telomere attrition activates a persistent DNA‑damage response (DDR) at chromosome ends, recruiting ATM/ATR and increasing local chromatin compaction.
2. This compaction spreads to nearby genes, including TPH1, decreasing histone acetylation and RNA polymerase II occupancy.
3. SIRT1, a NAD+-dependent deacetylase, normally counteracts DDR‑induced heterochromatin by deacetylating histones and promoting a permissive state at TPH1. SCFAs (especially butyrate) boost intracellular NAD+ levels and activate SIRT1 5.
4. With age, declining SCFA‑producing microbiota lower butyrate, reducing NAD+/SIRT1 signaling, thereby exacerbating telomere‑driven heterochromatin spread and silencing TPH1 6.
5. Consequently, EC cells produce less serotonin despite unchanged numbers, impairing gut motility and mucosal signaling 2.

Testable Predictions

• Prediction 1: Isolated EC cells from aged mice will show significantly shorter telomeres (quantified by Q‑FISH) and lower TPH1 mRNA/protein levels compared with young counterparts.
• Prediction 2: Pharmacological activation of SIRT1 (e.g., with resveratrol) or supplementation with sodium butyrate will rescue TPH1 expression

Hypothesis

The progressive rise in plasma VWF and FVIII with aging stems from a mitochondrial redox‑epigenetic switch in endothelial cells. We hypothesize that accumulated mitochondrial ROS stabilizes HIF‑1α, which then binds hypoxia‑response elements in the VWF promoter to drive transcription, while simultaneously suppressing ADAMTS13 expression through HIF‑1α‑dependent microRNA‑210 induction. This pathway operates alongside, but is mechanistically distinct from, the NO/ET‑1 and IL‑6/NF‑κB routes described in recent reviews[2][3]. If true, inhibiting mitochondrial ROS or HIF‑1α should blunt the age‑associated VWF/FVIII rise without affecting basal endothelial NO production.

Mechanistic Rationale

Aging endothelial cells exhibit increased mitochondrial electron‑leak, elevating superoxide and hydrogen peroxide[1]. These ROS inhibit prolyl hydroxylases, preventing HIF‑1α degradation and allowing its nuclear accumulation. HIF‑1α can directly activate the VWF gene via conserved hypoxia‑response elements, a mechanism demonstrated in hypoxic tumor endothelium but not yet explored in senescence. Parallelly, HIF‑1α upregulates microRNA‑210, which targets ADAMTS13 mRNA for degradation, reducing clearance of ultra‑large VWF multimers[1]. This dual action amplifies prothrombotic potential while leaving endothelial NO synthase activity relatively intact, explaining why VWF/FVIII rise coincides with preserved basal vasodilatory capacity in many older adults.

Experimental Design

1. Human endothelial isolation – Obtain umbilical vein endothelial cells (HUVECs) from donors ag

Hypothesis

Individuals with lower pain thresholds exhibit heightened hepatic inflammasome priming, which accelerates NAFLD progression independent of traditional metabolic risk factors.

Mechanistic Basis

Chronic pain sensitization and hepatic inflammasome activation share upstream drivers: mitochondrial ROS, TLR4 signaling, and SIRT1 suppression. We propose that nociceptor-derived neuropeptides—particularly substance P and CGRP—released during heightened pain signaling spill over into systemic circulation and directly modulate Kupffer cell activity. These peptides can activate NF‑κB and NLRP3 inflammasomes in liver macrophages, increasing IL‑1β and IL‑18 production. Simultaneously, sympathetic overdrive linked to pain hypersensitivity reduces hepatic SIRT1 expression, diminishing deacetylation of NLRP3 and further lowering the activation threshold for inflammasomes. This creates a feed‑forward loop where pain perception fuels hepatic inflammasome activity, and hepatic inflammasome outputs (IL‑1β, IL‑18) sensitize peripheral nociceptors via cytokine‑TRP channel interactions, reinforcing low pain thresholds.

Testable Predictions

1. In a cohort of asymptomatic adults, quantitative sensory testing (QST) for heat pain threshold will inversely correlate with hepatic NLRP3 inflammasome activity measured by circulating caspase‑1 p20 and IL‑18 levels, after adjusting for age, BMI, and alcohol intake.
2. Pharmacological blockade of substance P receptors (NK1R) or CGRP receptors will reduce hepatic IL‑1β release in ex‑vivo liver slice cultures stimulated with palmitate, ind

Hypothesis: Senescent stromal cells actively secrete a hematopoietic niche‑supportive SASP (e.g., G‑CSF, CXCL12, IL‑7) that boosts stem‑cell mobilization and immune competence of kin, providing an early‑life fitness benefit. This beneficial program is evolutionarily retained, but with age the same senescent cells shift toward a pro‑inflammatory SASP (IL‑6, IL‑1α, TNF‑α) due to cumulative DNA damage that activates cGAS‑STING and H2A.J‑dependent transcription, converting a supportive signal into chronic inflammaging. Thus aging can be viewed as a dysregulation of a normally adaptive senescence‑derived niche signal.

Mechanistic insight: CD36‑Src‑p38‑NF‑κB initiates the SASP transcriptional program [2]. In early senescence, the histone variant H2A.J accumulates and preferentially drives expression of niche‑supportive genes [4]. Persistent cytosolic DNA activates cGAS‑STING, which skews the secretome toward IL‑6/IL‑1α and sustains interferon signaling [3]. SASP‑induced CD38 expression in neighboring cells depletes NAD+, linking metabolic state to signal quality [5]. The balance between H2A.J‑driven and cGAS‑STING‑driven transcription determines whether the SASP supports hematopoiesis or drives inflammaging.

Predictions:

1. In young mice, inducible senescence in mesenchymal stromal cells (using p16‑3MR) will raise plasma G‑CSF and CXCL12, increase Lin⁻Sca1⁺cKit⁺ HSC frequencies, and enhance competitive repopulation; neutralizing G‑CSF or CXCL12 will block this effect without lowering IL‑6 levels.
2. Inducing DNA damage or overexpressing cGAS‑STING in senescent stromal cells

Hypothesis

Aged male muscle stem cells (MuSCs) exhibit heightened transposable element (TE) expression that triggers DNA‑sensing pathways, leading to localized loss of CTCF/cohesin binding at TAD boundaries. This boundary erosion permits ectopic enhancer–promoter contacts that shift H3K27ac from myogenic loci to inflammatory and extracellular‑matrix (ECM) enhancers, thereby locking MuSCs into a non‑productive state. Reinforcing CTCF occupancy at eroded boundaries—either by overexpressing CTCF or by stabilizing cohesin with a small‑molecule modulator—will restore proper 3D genome architecture, suppress inflammatory rewiring, and rescue myogenic differentiation despite persistent epigenetic drift.

Rationale

• et al. show that geriatric MuSCs lose ~38% of TAD insulation and gain H3K27ac at distal regulatory regions, correlating with activation of inflammatory/ECM pathways while myogenic genes retain mRNA levels but lose function {1}.
• Enhancer hierarchy studies demonstrate that an upstream enhancer loss renders a downstream enhancer inaccessible even when transcription factors are abundant, indicating that TAD integrity gates regulatory cascades {2}.
• Male MuSCs display a striking sex bias in TE activation (47 vs 9 TEs) and stronger interferon signaling {1}, suggesting that TE‑derived nucleic acids could activate cytosolic DNA sensors (cGAS‑S

Male mice gain ~20 % lifespan from a single AAV‑Klotho dose, yet females develop severe pathology despite comparable transgene expression [2][3]. This divergence hints at a sex‑dependent downstream effect rather than a simple expression issue.

We hypothesize that endogenous estrogen amplifies hepatic secretion of soluble Klotho, converting a beneficial circulating factor into a pathological hormone excess that disrupts the FGF23‑Klotho phosphate axis and triggers ectopic calcification, inflammation, and hepatic stress.

Estrogen receptors are highly expressed in hepatocytes and can up‑regulate secretory pathway genes, a phenomenon documented for other endocrine proteins [8]. In Klotho‑KO mice, dysregulated microRNAs and tRNA fragments suggest that Klotho loss perturbs RNA‑mediated translational control, hinting that excess Klotho could overwhelm similar regulatory loops in a sex‑specific manner [8].

If hepatic Klotho overproduction drives female toxicity, then redirecting expression away from liver and restricting it to a tissue that does not respond to estrogen‑mediated secretory up‑regulation should abolish the adverse phenotype while preserving longevity benefits.

We will generate an AAV‑PF‑TfR1 capsid (machine‑guided, liver‑detargeted, brain‑penetrant) that carries the Klotho cassette under a muscle‑specific creatine kinase (CK8) promoter coupled to a tetracycline‑responsive element (TRE) for doxycycline‑inducible control [1][4][5][6]. Male and female mice will receive the vector at 12 months of age, with doxycycline administered to achieve physiological Klotho serum

The gut microbiota shapes systemic immunity not only by triggering NLRP3 inflammasome activation but also by releasing metabolites that directly program T‑cell fate. I hypothesize that succinate, a TCA‑cycle intermediate enriched in dysbiotic microbiomes, acts as an upstream signal that amplifies NLRP3 signaling in innate immune cells and, through IL‑1β/IL‑18 release, stabilizes HIF‑1α in CD8⁺ T cells. HIF‑1α then transcriptionally programs the exhaustion circuit, increasing PD‑1, TIM-3 and TIGIT expression while suppressing mitochondrial oxidative phosphorylation. This creates a feed‑forward loop where exhausted T cells produce less IFN‑γ, further weakening mucosal barrier repair and perpetuating gut‑derived inflammation.

Key predictions: (1) Mice colonized with succinate‑producing strains (e.g., certain Bacteroides spp.) will show higher serum succinate, elevated NLRP3 caspase‑1 activity in lamina propria DCs, and increased HIF‑1α signaling in splenic and cerebral CD8⁺ T cells compared with germ‑free controls. (2) Genetic deletion of SUCNR1 (the succinate receptor) in DCs will blunt NLRP3 activation and reduce IL‑1β/IL‑18 despite dysbiosis. (3) Pharmacologic HIF‑1α inhibition (e.g., with PX‑478) will rescue T‑cell effector function and lower exhaustion marker expression even when succinate levels remain high.

To test this, we will run four experimental groups: (a) germ‑free mice + vehicle, (b) germ‑free mice + succinate‑producing consortium, (c) same as (b) but with DC‑specific SUCNR1 KO, and (d) same as (b) treated with HIF‑1α inhibitor. Readouts will include colonic b

NAD+ depletion during aging is not merely a byproduct of metabolic wear; it actively enforces a low‑autophagy state by shifting the Bcl‑2/Beclin-1 equilibrium toward inhibition. When nuclear NAD+ falls, SIRT1 deacetylase activity drops, leaving Bcl‑2 hyperacetylated. Hyperacetylated Bcl‑2 binds Beclin‑1 with higher affinity, blocking the nucleation step of autophagosome formation. This mechanism aligns with observed age‑related increases in Bcl‑2/Beclin-1 coupling that suppress autophagy across tissues [4].

A second layer amplifies the deficit. SIRT1 also deacetylates and destabilizes HIF‑1α under normoxic conditions. Reduced SIRT1 activity therefore allows HIF‑1α to accumulate, even when oxygen is plentiful. HIF‑1α drives transcription of CD38, the principal NAD‑consuming enzyme, and represses NAMPT, the rate‑limiting salvage enzyme [1][3]. The resulting surge in CD38 activity and fall in NAMPT expression pushes NAD+ levels lower, completing a feed‑forward loop that deepens SIRT1 inhibition and further stabilizes the Bcl‑2/Beclin-1 complex.

Thus, NAD+ loss functions as a checkpoint that deliberately downsizes cellular "ambitions" by locking autophagy off, conserving resources in a state the organism interprets as low future return.

Testable Predictions

1. Preventing Bcl‑2 acetylation (e.g., lysine‑to‑arginine mutations) will weaken Bcl‑2/Beclin-1 binding, restore autophagic flux, and partially rescue NAD+ levels in aged tissue despite elevated CD38.
2. SIRT1 overexpression in old mice will decrease acetyl‑Bcl‑2, lower Bcl‑2/Beclin-1 interaction, increase autophagy,

Hypothesis

Specific prebiotic fibers that selectively stimulate indigenous GABA‑producing Lactiplantibacillus plantarum strains increase luminal GABA, which in turn predicts greater clinical response to selective serotonin reuptake inhibitors (SSRIs) in depression.

Mechanistic Rationale

Prebiotics such as galactooligosaccharides (GOS) are fermented by gut microbes to short‑chain fatty acids (SCFAs) like butyrate. Butyrate acts as a histone deacetylase inhibitor, upregulating the gadB/gadC glutamate decarboxylase pathway in Lactobacillus, thereby boosting GABA synthesis 2. Elevated GABA can activate vagal afferents and modulate central neurotransmission, potentially synergizing with SSRI‑induced serotonergic signaling. This mechanistic link explains why generic prebiotic supplementation shows only weak antidepressant effects 1—only subsets of individuals harboring GABA‑competent Lactobacillus strains would benefit.

Testable Predictions

1. Baseline fecal metatranscriptomic abundance of gadB/gadC in Lactiplantibacillus correlates with subsequent SSRI response.

2. Administration of a GOS prebiotic for 4 weeks raises fecal GABA levels and enriches Lactobacillus gadB expression, but only in participants who initially possess the GABA‑producing genotype.

3. The magnitude of GABA increase mediates the improvement in Hamilton Depression Rating Scale (HAM‑D) scores after SSRI treatment, independent of changes in overall microbial diversity.

Hypothesis

Enteric nervous system (ENS)‑derived SASP factors actively suppress autophagy in peripheral tissues by driving HDAC‑mediated hyperacetylation of autophagy gene promoters, creating a systemic aging loop.

Mechanistic rationale

1. Senescent ENS neurons accumulate with age and secrete IL‑8, CXCL1, and other SASP components (see [3]). These cytokines can travel via the vagus nerve or circulation to reach liver, muscle, and brain.
2. SASP signaling activates NF‑κB and downstream HDACs in target cells. HDAC activity removes acetyl groups from histones, but paradoxically, HDAC inhibition (e.g., by butyrate) leads to hyperacetylation that represses Atg transcription ([4]). We propose that chronic SASP exposure shifts the balance toward HDAC over‑activity at specific promoters, causing hyperacetylation of repressive histone marks that silence Atg5 and LC3B.
3. Epigenetic silencing is reversible: treating aged mice with EGCG or vagotomy reduces SASP influx and restores autophagy ([2]), indicating the block is not due to lost machinery.
4. Feedback loop: suppressed autophagy in peripheral tissues amplifies cellular senescence, which further fuels ENS SASP secretion, tightening the circuit.

Testable predictions

• Prediction 1: Aged mice show elevated acetyl‑H3K9 at Atg5 and LC3B promoters in liver and muscle, correlating with plasma IL‑8/CXCL1 levels.
• Prediction 2: Chemical vagotomy or genetic ablation of serotonergic ENS neurons reduces hepatic Atg promoter acetylation and rescues autophagic flux in old mice.
• **Pre